Our study provides evidence that combination therapy with metformin and erlotinib could have therapeutic efficacy in cancers driven by EGFR and PI3K signaling, including a subset of BBC patients, and provides a rationale for clinical study. The gene discussed is EGFR; the disease is cancer.